Loading stock data…
TIL
$7.90-0.08 (-1.00%)
Market ClosedLast close May 1
Instil Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing a pipeline of novel therapies.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Instil Bio, Inc. in the Healthcare sector is trading at $7.90. The stock is currently near its 52-week low of $5.67, remaining 46.9% below its 200-day moving average. Technical signals show neutral RSI of 39 and bearish MACD signal, explaining why TIL maintains its current current market pressure. The Whystock Score of 40/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Neutral momentum (RSI 39) — price action in range
Long-term trend bearish (Price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price$7.90
Potential Upside
5%
Whystock Fair Value$8.29
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Analyst Consensus1 analysts
Hold
Mean target$7.00-11.4%
Range$7.00 – $7.00
Fundamentals
Instil Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing a pipeline of novel therapies. Its lead products candidate is AXN-2510/IMM2510 that is in Phase 1b/2 clinical trial for the treatment of patients with chemotherapy in...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$57.04M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
2.03
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-197.32%
Volume
Today's trading volume
8,393
Recent News
CarMax Stock Down 47% This Past Year, But One Fund Is Betting $6 Million on a Turnaround
CarMax runs a nationwide network of used car stores and digital channels, offering multi-channel sales and financing to U.S. consumers.
Alumis Stock Has Rallied 250% This Past Year. One Fund Sold Its $5 Million Stake Last Quarter.
This clinical-stage biotech develops therapies targeting autoimmune and neuroinflammatory diseases with a focus on TYK2 inhibition.
Instil Bio, Inc. (NASDAQ:TIL) is definitely on the radar of institutional investors who own 36% of the company
NasdaqCM:TIL 1 Year Share Price vs Fair Value Explore Instil Bio's Fair Values from the Community and select yours Key...
Instil Bio, Inc. (TIL) Is Up 4.07% in One Week: What You Should Know
Does Instil Bio, Inc. (TIL) have what it takes to be a top stock pick for momentum investors? Let's find out.
Wall Street Analysts Think Instil Bio (TIL) Could Surge 246.68%: Read This Before Placing a Bet
The mean of analysts' price targets for Instil Bio (TIL) points to a 246.7% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.